This report provides a guide for selecting high-quality commercial antibodies against NACHT, LRR, and PYD domains-containing protein 3 (NLRP3). Fourteen anti-NLRP3 antibodies were evaluated using western blot analysis with THP-1 WT and NLRP3 KO lysates, treated and untreated with PMA, as well as with culture medium. Immunoprecipitation experiments were conducted using THP-1 WT and NLRP3 KO lysates, treated and untreated with PMA. The characterization data was generated using a standardized protocol that compares read-outs in knockout cell lines and their isogenic parental controls. Thank you to the Work Michael J. Fox Foundation for Parkinson's Research for nominating this target and supporting the study.